Genmab A/S (NASDAQ: GMAB) is one of 596 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Genmab A/S to related companies based on the strength of its profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
This table compares Genmab A/S and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Genmab A/S Competitors||-2,502.83%||-853.69%||-32.24%|
This table compares Genmab A/S and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Genmab A/S||$479.18 million||$233.19 million||6.26|
|Genmab A/S Competitors||$2.11 billion||$223.53 million||-3.39|
Genmab A/S’s rivals have higher revenue, but lower earnings than Genmab A/S. Genmab A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations for Genmab A/S and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Genmab A/S Competitors||5791||15771||31486||1210||2.52|
Genmab A/S currently has a consensus price target of $23.67, suggesting a potential upside of 0.54%. As a group, “Pharmaceutical preparations” companies have a potential upside of 48.03%. Given Genmab A/S’s rivals higher possible upside, analysts clearly believe Genmab A/S has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
19.6% of Genmab A/S shares are held by institutional investors. Comparatively, 45.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Genmab A/S beats its rivals on 7 of the 12 factors compared.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.